View Post

Veliparib Leads to PFS Boost in Certain Breast Cancer Subsets

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: targetedonc.com “In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo.” When administered with carboplatin and paclitaxel,the PARP inhibitor veliparib increased progression-free survival (PFS) in patients with hormone receptor–positive breast cancer and triple-negative breast cancer (TNBC) who were positive for germline …

View Post

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com The PARP inhibitor veliparib increased progression-free survival (PFS) in women with hormone receptor (HR)-positive breast cancer and triple-negative breast cancer (TNBC) who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694), presented during the 2020 ESMO Breast Cancer Virtual Meeting. “In both subgroups, …